report cf franchis revenu vs consensu non-
gaap ep vs consensu revenu guidanc bracket consensu
result tripl track fda file first
tripl regimen anticip mid-year expect industry-lead top-lin
growth thru remain top pick
vertex report cystic fibrosi cf franchis revenu q/q
y/i ahead consensu estim revenu
includ kalydeco sale q/q y/i orkambi q/
 y/i symdeko revenu q/q combin non-gaap
sg vs yield non-gaap ep ahead
consensu
vertex provid guidanc includ total cf product revenu
bracket consensu combin non-gaap sg
tax rate base current trend guidanc cf franchis
estim increas y/i non-gaap ep estim
increas
notabl tonight call disclos patent
expect last somewhat longer prior assumpt ad
extra year exclus dcf analysi increas price target
vertex conduct patient phase trial tez/iva /-
homozygot patient phase trial tez/iva vs placebo
het min patient trial util primari efficaci endpoint week
longer follow addit safeti efficaci analys week beyond
enrol pivot trial complet novemb top-lin
data read
follow top-lin data read-out vertex choos best regimen
submit regul nda slate submiss base
efficaci safeti data assum rapid fda file prioriti review vertex
tripl could market end earli
ex-u submiss plan late prior phase data read-
european regul request efficaci data support regulatori
submiss howev vertex plan discuss european regul
phase trial read given extent benefit
seen week vertex hope tripl regimen contain
efficaci data superior could approv base efficaci data
earlier time point perhap data similar
tripl gener kalydeco-lik efficaci studi thu far appear
similar breakthrough treatment cystic fibrosi kalydeco compel clinic
profil drove rapid adopt mani market larg penetr within quarter
pleas see page report import disclosur
cftr potenti kalydeco standard care cf patient gate partial loss
function mutat also develop regimen contain kalydeco cftr
corrector lumacaftor tezacaftor potenti address cf patient
harbor least one allel orkambi lumacaftor kalydeco approv
juli symdeko tezacaftor kalydeco februari tripl combin
contain gener corrector well tezacaftor ivacaftor produc impress
ph data fda file anticip tripl regimen appear
repres true breakthrough treatment improv qualiti life extend
life span patient model assum cystic fibrosi patient one
vertex therapi drive nearli franchis sale dcf-base price
target
initi data ph trial tez/iva
result ph ii
acut pain follow bunionectomi
file fda approv first tripl
regimen cf
cystic fibrosi patient
one vertex therapi
drive franchis sale
franchis maintain exclus
rest pipelin contribut
cystic
fibrosi patient one vertex
therapi drive
franchis sale
franchis maintain exclus
anoth vertex pipelin program
fewer cystic
fibrosi patient one vertex
therapi drive less
franchis sale
vertex face meaning competit
vertex leader treatment cystic fibrosi orkambi kalydeco standard
therapi cystic fibrosi patient homozyg mutat
rate residu function mutat vertex gener posit phase data
tripl combin regimen incorpor second gener corrector
min patient result second tripl regimen contain expect
tripl regimen appear repres true breakthrough treatment
improv qualiti life extend life span cystic fibrosi
world-wide moreov patent protect late vertex franchis
long commerci life early-stag pipelin includ candid
antitrypsin defici pain sickl cell diseas beta-thalassemia focal segment
symkevi approv eu novemb drug reimburs
avail patient germani ireland denmark netherland addit
ph program adult near complet vertex initi
studi children age support eventu label expans
initi phase ii studi once-daili potenti support develop
part once-daili tripl vertex crispr initi ph i/ii studi
sickl cell diseas beta-thalassemia data expect phase iib dose-
rang studi inhibitor acut pain follow bunionectomi test
multipl dose oral formul sever pain molecul advanc late-
stage preclin develop clinic trial first molecul slate
final vertex sever candid treatment fsg preclin develop
compani aim bring first clinic
decemb vertex initi phase trial antitrypsin defici
drug healthi volunt sever small molecul corrector advanc
preclin develop well
manag think proof-of-mechan data could gener rel short term
studi mechan corrector would increas amount correctli
fold simpli measur level function blood would provid
evid efficaci
vertex cystic fibrosi franchis continu perform well appear pois drive
industry-lead growth next decad vertex tripl cf regimen
produc impress breakthrough-qu phase result last year provid visibl
next driver revenu growth data tripl anticip
later quarter vertex file best perform regimen fda approv
impli launch earli tripl demonstr dramat
improv lung function like extend life expect rapidli
broadli adopt base promis tripl regimen project
revenu compound-annual-growth-rate non-gaap ep compound-annual-growth-rate highest
larg cap biotech patent protect exclus late tripl
regimen long lucr commerci live moreov anticip
potenti non-cf pipelin becom clear
least candid earli clinic test larg cap univers middl
growth prospect think fundament posit vertex must biotech
larg cap growth investor expect vertex stock appreci price target
tripl regimen approach commerci launch vertex non-cf pipelin gener
vertex leader discoveri develop candid treat cystic
fibrosi vertex first cystic fibrosi commerci product kalydeco ivacaftor
cftr potenti compound kalydeco approv fda
januari patient gate mutat mutat
addit residu function mutat subsequ ad label
seri supplement approv estim kalydeco achiev
world-wide sale patient gate
defect partial loss function cftr mutat vertex also develop
regimen contain kalydeco cftr corrector lumacaftor tezacaftor
potenti address cf patient harbor least one allel
orkambi lumacaftor ivacaftor succeed two pivot trial june
approv juli symdeko tezacaftor ivacaftor
produc posit data two phase trial march fda approv
februari european approv came novemb brand
name symkevi expect orkambi symdeko wide adopt
cystic fibrosi patient homozyg mutat world-wide
improv potenc orkambi symdeko homozygot
effect patient one copi allel vertex
advanc second gener corrector clinic develop act
synergist lumacaftor tezacaftor complet correct
fold defect cftr tripl combin contain tezacaftor
ivacaftor four second gener corrector produc impress
phase ii proof-of-concept data tripl regimen result mean absolut
improv percentag point percentag point
patient four tripl regimen well toler base
proof-of-concept data vertex move two once-daili second gener
corrector phase homozyg
heterozyg patient result high end
expect produc improv among untreat het min
patient increment improv among homozyg
patient rel tez/iva alon result anticip
vertex expect file fda approv tripl regimen het
min patient impli launch tripl regimen appear
repres true breakthrough treatment improv qualiti life
extend life span patient cystic fibrosi world-wide
moreov second gener corrector expect patent protect
vertex franchis long commerci life model
assum cystic fibrosi patient one vertex therapi
drive almost franchis sale dcf-base price target
result two pivot trial tripl combin tezacaftor ivacaftor
data phase iib dose-rang studi oral bunionectomi surgeri
initi phase ii studi monotherapi cf patient gate mutat
file fda approv first tripl regimen
possibl gener proof-of-concept data
initi clinic develop first pain molecul preclin develop
initi clinic develop fsg
partner releas phase data pimodivir influenza hospit patient
cowen compani
cowen compani
statesnumb patient diagnos patient penetr patient per patient patient gate gate penetr patient per patient patient gate mutat homozyg homozyg regimen penetr patient vertex per patient patient heterozyg heterozyg regimen penetr patient vertex per patient hetero patient vertex kalydeco orkambi/symdeko/tripl cystic fibrosi revenu patient diagnos patient penetr patient per patient gate gate penetr patient per patient patient gate homozyg regimen penetr patient vertex per patient heterozyg heterozyg regimen penetr patient vertex per patient hetero row patient vertex kalydeco orkambi/symdeko/tripl cystic fibrosi revenu kalydeco kalydeco orkambi orkambi/symdeko/tripl cystic fibrosi patient vertex cystic fibrosi cowen
cowen compani
fy dec except per symdeko tripl growth expensesroyalti payment royaltiescost good product develop ex gener administr ex base cost loss incom rate incom loss attribut non-controlling lncome exclud soe exclud soe expens net share share cowen
cowen compani
fy dec except per cagrrevenu kalydeco symdeko tripl growth expensesroyalti payment royaltiescost good product develop ex gener administr ex cost incometot loss incom rate lncome exclud soe exclud soe expens net share cowen
cowen compani
financi year incivek cystic fibrosi payment tax asset unus tax free year growth ratetermin valu termin valu net per valu calcul cowen
calcul target price employ one valuat methodolog
includ discount earn analysi discount cash flow analysi net present
valu analysi and/or compar compani analysi analys may may
requir use object measur price-to-earn price-to-sal multipl
well subject measur discount rate
make invest recommend earli stage pre-commerci biotechnolog
compani base upon assess technolog probabl pipelin
success potenti market opportun event success howev
compani lack tradit financi metric believ good
methodolog assign specif target price stock
multipl risk inher invest biotechnolog sector
beyond system risk also clinic regulatori commerci risk addit
biotechnolog compani requir signific amount capit order develop
clinic program capital-rais environ alway chang risk
necessari capit complet develop may readili avail
vertex deriv great major revenu two relat product kalydeco
orkambi forecast sale franchis difficult outlook could
alter new safety/efficaci find emerg competit alter medic
treatment paradigm chang pricing/reimburs environ vertex
stock price could also affect chang outlook key pipelin program
includ second gener corrector evalu market potenti
drug yet approv particularli riski
